Astellas Reaches Agreement to Obtain Iveric Bio


Acquisition expected to support pharmaceutical’s blindness regeneration campaign.

 Licensed   FILE #:  536976248  Preview Crop  Find Similar DIMENSIONS 5760 x 3840px FILE TYPE JPEG CATEGORY People LICENSE TYPE Standard or Extended an elderly woman on a computer tomograph does a retinal tomography in the oculist's office. Image Credit: Adobe Stock Images/Olga

Astellas Pharma Inc., a Tokyo-based pharmaceutical company, is officially taking control of Iveric Bio, a biopharmaceutical company focused on the development of treatments for retinal diseases. Per the terms of the deal, Iveric Bio will become a wholly owned subsidiary of Astellas with a value of US $40 per share.

Closing the acquisition, which is expected to be complete by Q3 of this year, is still subject to approval by Iveric Bio’s stockholders.

"We are pleased to reach an agreement with Iveric Bio, a company with exceptional expertise in the R&D of innovative therapeutics in the ophthalmology field." said Naoki Okamura, President and CEO, Astellas. "Iveric Bio has promising programs including avacincaptad pegol, an important program for geographic atrophy secondary to age-related macular degeneration, and capabilities across the entire value chain in the ophthalmology field. We believe that this acquisition will enable us to deliver greater value to patients with ocular diseases at high risk of blindness."

Reference: Astellas Enters into Definitive Agreement to Acquire Iveric Bio. April 29, 2023/PR Newswire

Related Videos
Related Content